Company ProfilePremium

Artemis Medicare Services Limited

Company Profile Analysis

Tickers: ARTEMISMED.NS, 542919.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Artemis Medicare Services Limited - Company showcase

Year Founded & Workforce

2004

Artemis Medicare Services Limited logo

Artemis Medicare Services Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Artemis Medicare Services Limited Overview

Artemis Medicare Services is a promoter-backed, quaternary-care hospital operator. Its economics are still dominated by one asset: the JCI- and NABH-accredited Artemis Hospital in Gurugram. That hospital has 700 beds of built capacity and about 544 operational beds, and it produced roughly 97% of consolidated revenue in Q1 FY27. The Company competes in the crowded Delhi-NCR tertiary-care market against much larger peers: Medanta, Fortis, Max and Apollo. Its differentiation rests on a high-acuity case mix (oncology, neurosciences, cardiac sciences, transplants), on management's claim of the highest ARPOB in NCR (about INR 85,690 in Q1 FY27), and on an unusually large international-patient franchise (27–34% of Gurugram revenue). Artemis is now moving from a single-flagship model to a multi-site network. Its tools are brownfield FAR-led expansion at Gurugram, an asset-light Medical Services Agreement model (Raipur, opened July 2026; VIMHANS South Delhi, targeted for FY29) and a proposed INR 700 crore equity raise. The stated target is 2,000–2,300 beds by 2029.


What the Company does

Artemis Medicare Services owns, operates and manages multi-specialty and super-specialty hospitals. Its activity is concentrated in the Delhi National Capital Region (NCR). It is now extending into Central India (Raipur, Chhattisgarh), with management/operations arrangements in Mauritius. Company boilerplate in the Q3 FY26 press release says Artemis operates 800+ beds, mainly in Delhi-NCR, including the 700+ bed flagship Gurugram hospital. It also cites cardiac centres run with Philips under the Artemis Cardiac Care brand, and an overseas presence in Mauritius through an operations arrangement (Q3 FY26 press release, 2 Feb 2026).

Screener's company description, which is derived from Company disclosures, characterises the business as running multi-specialty hospitals in Haryana under the Artemis Hospitals brand. It lists cardiology, oncology, orthopaedics, neurology, nephrology, gastroenterology and critical care among the specialties.

Business and revenue model

Revenue model componentDescriptionDisclosure status
In-patient services (IP)Bed-day, procedure, surgical, ICU, pharmacy and consumables billed per admission. This is the core of ARPOB. Q1 FY27 Gurugram IP volume was 9,181.Q1 FY27 investor materials (via Multibagg summary)
Out-patient services (OP)Consultations, diagnostics, day-careOP split not publicly disclosed in retrieved sources
International patients (medical value travel)27% (Q1 FY27) to 34% (Q3 FY26) of Gurugram revenue; Q1 FY27 international revenue was INR 76.51 croreQ1 FY27 and Q3 FY26 releases
Payor channelsQ1 FY27 Gurugram mix: international 27%, insured 33%, domestic cash 23%, government schemes 17%Q1 FY27 investor materials
Asset-light hospital management (MSA / long-term agreements)Artemis brands and operates hospitals owned by third parties (VIMHANS South Delhi MSA, Feb 2026). Raipur Artemis Shanti operates under a long-term agreement. Mauritius is an operations arrangement.NSE intimation 20 Feb 2026; Sahi summary of Q1 FY27 filing
Allied / satellite formatsArtemis Lite (neighbourhood multi-specialty), Daffodils by Artemis (women & child), Artemis Cardiac Care (JV with Philips), Artemis Solace (described by AlphaStreet as one of the diversification models; scope not detailed in sources)IFC release Apr 2024; AlphaStreet; CARE 2023

There is no material product, subscription or licensing revenue. Management and brand fees from MSA arrangements are an emerging and still undisclosed component.

Value-chain position, customers and end-markets

Artemis sits at the tertiary and quaternary end of the provider chain. It receives referrals from primary and secondary providers, from international facilitators and from insurers and TPAs. Its customers are:

  • Domestic self-pay patients.

  • Privately insured patients (via insurers and TPAs).

  • Corporate employer programmes.

  • Government scheme beneficiaries (central and state schemes, contributing 17% of Q1 FY27 Gurugram revenue).

  • International patients. Management cited resilience despite West Asia geopolitical tension in Q1 FY27 (ScanX summary of Q1 FY27 call).

The specialty mix is weighted to high-acuity care. Oncology contributed 19% and neurosciences 15% of the revenue mix (AlphaStreet Q3 FY26 summary).

Independent characterisation

Artemis is best understood as a single-asset quaternary hospital with a regional-network option attached. Its quality metrics (ARPOB, international mix, accreditation) are competitive with NCR's top tier. Its scale is roughly one-tenth of the large listed chains. FY26 consolidated PAT was about INR 104 crore, against INR 1,000–1,950 crore for Apollo, Max and Fortis (Fyers peer snapshot). The investment case over FY27–FY29 rests on three things: utilisation (lifting Gurugram occupancy from about 65% to 70%+), FAR-led brownfield capacity at near-zero land cost, and execution of capital-light MSAs. Rising other-income and falling interest costs flatter recent PAT growth. The core operating improvement is real, though: EBITDA rose 27.9% YoY on 12.7% revenue growth in Q1 FY27.

Strategy

Stated strategic themes (paraphrased from FY26 calls and releases)

  1. Scale from about 800 to 2,000–2,300 beds by 2029. Management described this as moving Artemis from a 700–800-bed group to roughly 2,300 beds (Q3 FY26 call, 3 Feb 2026). Sharekhan cites an earlier target of 1,700+ beds by FY29.

  2. Sweat the flagship first. The plan is to lift Gurugram occupancy to about 70%, and to commission an extra ~100 beds only once occupancy reaches 70% (Q4 FY26 call notes). Management projected about 70% by Q2 FY27 and 68–70% for the year.

  3. Near-zero-cost brownfield. The IGBC Platinum certification adds 15% FAR (100–125 beds at no land cost). Purchased FAR up to 2.15 would add about 200 more beds, taking Gurugram to 950–1,000 beds.

  4. Capital-light network expansion through MSAs and long-term agreements. Examples are Raipur (operational) and VIMHANS South Delhi (650+ beds). Further projects are "in the funnel".

  5. Protect pricing and case mix. Management guides 4–6% annual ARPOB growth and points to quaternary programmes such as heart and lung transplant and oncology.

  6. Medical value travel. The international franchise is to be sustained at 27–34% of flagship revenue.

  7. Digital and clinical technology. AI-assisted triage has been deployed across hospitals.

Initiatives register (last 24 months)

DateInitiativeTypeTargets / detail
Apr–May 2024IFC INR 330 crore CCDCapital / strategic investorBed capacity, new specialties, cardiac centres in Tier-2/3 cities
FY25ABTP physiotherapy partnershipPartnershipTech-enabled physio
FY25–FY26Gurugram third tower (700 beds)BrownfieldRamp to 70% occupancy
FY26IGBC Platinum certificationESG / capacity+15% FAR, about 100–125 beds
FY26AI-assisted triageDigitalShorter wait times
Feb 2026INR 700 crore fund-raise approvalCapitalFunds new hospitals, Gurugram organic growth, VIMHANS beds; target net debt of INR 250–280 crore (Angel One)
20 Feb 2026VIMHANS Artemis Hospital MSAAsset-light expansion450 beds by FY29, then 650+
2,026Heart & Lung Transplant CentreClinicalNorth India thoracic transplant hub
9 Jul 2026Artemis Shanti Hospital, RaipurGreenfield / long-term agreementBreakeven 15–24 months
Jun–Jul 2026Fund-raise of up to INR 700 crore re-approved (Board 18 Jun; postal ballot 20 Jul)CapitalQIP/preferential; analysts (Analytics Insight) link part of it to acquisitions
FY26Mauritius Cascavelle (110 beds)International O&MAnnounced for FY26

Medium-term guidance (management, FY27)

ItemGuidanceSource
Gurugram occupancyAbout 70% by Q2 FY27; 68–70% by end-FY27Q1 FY27 and Q4 FY26 calls
ARPOB growth4–6% YoY sustainable; 4–5% expected near termQ4 FY26 and Q1 FY27 calls
Absolute EBITDAContinued expansion in FY27Q4 FY26 call
Raipur breakeven18–24 months from launch (some summaries say 15–18 months to EBITDA-positive)Q4 FY26 call; Sahi
Bed capacity2,000–2,300 beds by 2029Q3 FY26 call
VIMHANSPhase 1 (~450 beds) by FY29NSE intimation

Explicit revenue or margin targets in numeric form for FY27–FY29 were not publicly disclosed.

Products & Services

Artemis' "products" are clinical service lines, hospital formats and enabling programmes. Pricing is per-episode, under tariff schedules that are not published as company-wide disclosures. Third-party medical-tourism listings are cited where they exist and flagged as such.

Centres of Excellence (Gurugram flagship)

CentreScope / capabilitiesTarget customerNotes / flagship offerings
Artemis Heart Centre (incl. Artemis Parmanand Heart Centre)Interventional cardiology, cardiac surgery, electrophysiology, structural heartDomestic and international cardiac patientsThird-party listing (Bookimed) shows heart valve replacement at about USD 10,225–12,270 (not Company-verified)
Heart & Lung Transplant CentreHeart, lung and combined heart-lung transplants; mechanical circulatory supportNorth India transplant candidates; insurer and government-scheme tie-ups being pursuedLaunched 2026 with Dr. Sandeep Attawar. Positioned as North India's integrated thoracic transplant hub; follows ISHLT guidelines and reports to the Indian Heart & Lung Transplant Registry; paediatric transplants planned
Artemis Cancer CentreMedical, surgical and radiation oncology; adult and paediatricHigh-acuity oncology, international patientsOncology about 19% of revenue mix
Artemis Neurosciences Centre (incl. CyberKnife centre)Neurosurgery, neurology, stereotactic radiosurgeryComplex neuro casesNeurosciences about 15% of revenue mix
Artemis Organ Transplant CentreLiver, kidney, pancreas, bone-marrow (autologous/allogeneic), corneaTransplant patients, internationalThird-party sources describe Artemis as Haryana's first licensed renal transplant centre (historical claim, not re-verified)
Joint Replacement & OrthopaedicsArthroplasty, sports medicine, spineDomestic and internationalABTP physiotherapy partnership supports rehab
Minimally Invasive & Bariatric SurgeryLaparoscopic, robotic-assisted (platform not disclosed), bariatricElective surgical—
GastrosciencesGI medicine, hepatology, GI surgery——
Critical Care & PulmonologyICU, pulmonology——
Women & Child CentreObstetrics, gynaecology, neonatology, paediatricsFamiliesComplemented by Daffodils
Emergency & Trauma Centre24x7 emergency, traumaCatchment—
Dermatology, Cosmetology & Plastic SurgeryAesthetic and reconstructiveSelf-pay—
Pain Medicine & Palliative CarePain interventions, palliativeChronic / oncology—

Source for the centre list: Artemis organisational descriptions reproduced on third-party profiles (Prospeo) and medical-tourism listings. These match the website's Centres of Excellence. Launch years for individual centres are not publicly disclosed, except the 2026 Heart & Lung Transplant Centre.

Hospital formats and brands

Brand / formatDescriptionLocationsLaunchStatus
Artemis Hospital (flagship)JCI- and NABH-accredited quaternary super-specialtySector 51, Gurugram2,007700-bed capacity (third tower); 544 operational beds in Q1 FY27
Artemis LiteNeighbourhood multi-specialty hospitalsNFC (Delhi); Sector 82A (Gurugram)c. FY23Operating
Daffodils by ArtemisLuxury women & child hospitalsSector 40 (Gurugram); East of Kailash (Delhi)c. FY23Operating
Artemis Cardiac CareCardiac centres in Tier-2/3 cities, JV with PhilipsSeven centres (2024); Chennai closed Jan 2025c. FY23Operating
Artemis SolaceListed by AlphaStreet among diversification models——Scope not publicly detailed
Artemis Shanti Hospital300+ beds, 50+ specialties, 11 Centres of ExcellenceDevendra Nagar, Raipur9 Jul 2026Ramp-up; breakeven guided at 15–24 months
VIMHANS Artemis Hospital650+ bed super-specialty under MSA with VIMHANSNehru Nagar, South DelhiTarget FY29 (phase 1, ~450 beds)Construction phase
Artemis Curepipe Hospital80-bed hospitalCurepipe, MauritiusFY24Operating (operations arrangement)
Artemis Cascavelle Hospital110-bed hospitalCascavelle, MauritiusAnnounced for FY26Opening status not confirmed in retrieved sources
OPTIC ClinicMedical Dialogues reports Artemis launched its "first OPTIC Clinic"; scope not detailed—2,026Not detailed

Enabling and service programmes

ProgrammeDescriptionYear
International patient servicesFacilitation, travel and visa assistance; 27–34% of Gurugram revenueOngoing
AI-assisted triageImplemented across hospitals in FY26; management says it cut wait timesFY26 (Q4 FY26 call)
ABTP physiotherapyTechnology-enabled sports and rehab physiotherapy with Abhinav Bindra Targeting PerformanceFY25
Green building (IGBC Platinum)Gurugram campus certification; unlocks 15% additional FARFY26

Financial Narrative

Primary sources:

  • FY24 and FY25: Directors' Report FY25.

  • FY26: Q4 FY26 / FY26 press release and integrated filing.

  • FY22–FY23 and line items not in releases: StockAnalysis (S&P-sourced standardisation of filings), converted from INR million to INR crore.

  • "Gross profit" uses the aggregator's cost-of-revenue classification; it is not a Company-reported metric.

  • All figures are consolidated unless labelled standalone.

Income statement (consolidated, INR crore)

Notes:

  • The standalone PBT for those years comes from Screener's 13-column row (assigned Mar-14 to Mar-25 plus TTM) and is approximate.

  • FY2026 PBT of INR 139.18 crore and net profit of INR 103.62 crore are from the Fyers summary of filings. ScanX reports FY26 net profit of INR 103.72 crore (+26.2%), so the two sources differ marginally.

  • For reference, reported quarterly diluted EPS was INR 1.98 in Q1 FY27 (+46.7%) and INR 1.90 in Q4 FY26.

  • FY26 DPS is the final dividend of INR 0.45 approved at the 22nd AGM (record date 10 Jul 2026). FY24–FY25 DPS is implied by the aggregator's "0% dividend growth" and the 0.17% yield.

EBITDA

Notes:

  • FY26 consolidated EBITDA of INR 21,801 lakh is from the FY26 press release as reproduced by Indian Pharma Post. It is consistent with the reported 9M FY26 EBITDA margin of 20.2% plus Q4 EBITDA of INR 59.38 crore.

  • Quarterly back-calculation suggests FY25 consolidated EBITDA of roughly INR 175–185 crore, which conflicts with Screener's standalone INR 150 crore. That figure may be stale or computed on a different basis.

  • For Q3 FY26, ScanX cites EBITDA of INR 52 crore and Sharekhan cites INR 44.6 crore (16.4% margin). This is an unresolved source discrepancy, possibly due to treatment of other items.

Margin profile

Revenue CAGR FY2022–FY2026: about 18.2% (INR 554.8 crore to INR 1,081.2 crore over four years). The three-year CAGR from FY2023 to FY2026 is about 13.6%.

Commentary:

Volume reset (FY22–FY23): revenue grew 33–36% a year as volumes recovered from COVID and Gurugram beds expanded (363 to 427 per CARE).

Capacity absorption (FY24–FY25): growth slowed to 19% and then 6.6% as the second and third towers came on stream and utilisation lagged. FY25's slow top line coincides with occupancy around 61–64%.

Operating leverage (FY26–Q1 FY27): EBIT margin widened about 450 bp over four years, to 13.1%. Q1 FY27 operating margin excluding other income was 19.64%, the highest in at least eight quarters (MarketsMojo).

Below-the-line support: FY25 PAT growth of 68% was helped by interest income of about INR 26.6 crore on IFC CCD proceeds, up from INR 4.3 crore in FY24. Other income has since declined as these funds are spent on expansion (Q1 FY27 commentary).

Balance sheet (consolidated, INR crore)

Notes:

  • FY22–FY25 borrowings are standalone (Arihant/CMOTS); FY26 is consolidated (MarketsMojo; integrated filing).

  • FY26 borrowings split into non-current INR 189.95 crore and current INR 36.91 crore (integrated filing, 31 Mar 2026).

  • The aggregator's "short-term investments" excludes bank deposits. The FY26 integrated filing shows other bank balances of INR 172.74 crore in addition to cash of INR 33.41 crore. Including these, FY26 net borrowings were only about INR 21 crore. The Company separately reported outstanding borrowing of INR 225.70 crore as of 31 Mar 2026 in its "not a large corporate" disclosure (29 Apr 2026).

  • Goodwill is not separately disclosed in retrieved data and is presumed nil or immaterial.

  • FY25 equity jumps because the INR 330 crore IFC CCDs are classified within equity, being compulsorily convertible. They converted to 1.89 crore shares in Nov 2025.

Cash flow (consolidated, INR crore)

Notes:

  • Source is StockAnalysis, converted from INR million.

  • Capex is derived as operating cash flow minus FCF.

  • FY25 debt issued includes the IFC CCDs.

  • FY26 investing cash flow includes INR 134.9 crore that the aggregator classifies as "cash acquisitions". It most likely represents capital advances or security deposits for the MSA/long-term-agreement hospitals; other long-term assets rose to about INR 227.6 crore.

  • Dividends paid were roughly INR 6 crore a year (derived as about 134–138 million shares × INR 0.45).

  • No share buybacks were made in the period.

Ratios

Notes:

  • Ratios are computed by the analyst from the tables above. FY22 average equity uses the FY21 standalone figure (INR 321.6 crore).

  • Net debt/EBITDA for FY26 is about 1.05x on the aggregator basis (INR 228.2 crore / INR 218.0 crore). Including bank deposits it is about 0.1x.

  • ROIC is not publicly disclosed. Screener reports ROCE of 14.6–14.9% (2026 snapshots) and ROE of 12.9%.

Ratio commentary:

Balance sheet repair: the IFC CCD (FY25) and its conversion (FY26) took gearing from 0.71x to 0.28x. CareEdge cited this strengthening in its 2024 upgrade.

Coverage: interest coverage has recovered to 5.8x, and quarterly interest fell from INR 7.38 crore to INR 6.46 crore between Q1 FY26 and Q1 FY27.

Returns: ROE is stuck at 11–13% because equity rose ahead of earnings. The three-year average ROE of 11.7% is flagged by Screener as a weakness.

Working capital: the hospital business runs a modest cash cycle of about 36–47 days. Receivables from government schemes and international facilitators are the main drag.

Quarterly run-rate (consolidated, INR crore)

Sources: Fyers quarterly data; Q2 FY26 (revenue INR 27,470 lakh, PAT INR 3,000 lakh); Q3 FY26 release (PAT INR 2,223 lakh, +7.9%); Q4 FY26 release (PAT INR 3,028 lakh, +32.1%); Q1 FY27 release (PAT INR 31.44 crore, +48.3%). Q1 FY27 PBT was INR 42.63 crore (+43.2%) and other income INR 5.37 crore.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Revenue by Segment (%)

MetricQ3FY25Q4FY25Q1FY26Q3FY26Q4FY26Q1FY27

Consolidated revenue (INR Cr)

232.4239.9255.0272.4279.2287.3

Artemis Hospital Gurugram revenue (INR Cr)

217.1225.2241.3260.9267.5278.5

Gurugram share of consolidated (%)

93.493.994.695.895.896.9

Results by Segment and Segment Margins & Growth (%)

MetricQ4FY25Q1FY26Q4FY26Q1FY27

Consolidated EBITDA (INR Cr)

48.248.359.461.8

Gurugram EBITDA (INR Cr)

48.149.558.061.6

Consolidated EBITDA margin (%)

20.118.921.321.5

Business Units

UnitWhat it containsFinancial disclosure

Artemis Cardicare Pvt Ltd (65% subsidiary; JV with Philips)

Artemis Cardiac Care centres (seven centres in Apr 2024, mainly Tier-2/3 cath-lab-led cardiac units; Chennai closed Jan 2025)

Not publicly disclosed separately

Artemis Lite

Neighbourhood multi-specialty hospitals (NFC Delhi; Sector 82A Gurugram per Artemis profile listings)

—

Daffodils by Artemis

Women & child hospitals (Sector 40 Gurugram; East of Kailash, Delhi)

—

Artemis Shanti Hospital, Raipur

300+ bed super-specialty (some summaries cite 200 beds added under a long-term agreement), opened 9 Jul 2026

Gestation; costs tracked separately per management

Mauritius (Curepipe 80 beds; Cascavelle 110 beds announced)

Operations/management arrangement

—

VIMHANS Artemis Hospital (South Delhi)

650+ bed MSA; commissioning targeted for FY29

Pre-operational

“—” = not publicly disclosed.

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

554.8737.4878.6936.91,081.2

Revenue growth YoY (%)

35.932.919.16.615.4

Total income incl. other income (INR Cr)

558.7744.8885.9969.91,111.1

Gross profit, aggregator basis (INR Cr)

91.9138.1177.6197.7237.7

Operating income EBIT ex other income (INR Cr)

46.563.993.5108.1142.1

Interest expense (INR Cr)

9.417.327.828.524.5

Profit before tax, consolidated (INR Cr)

——68.5107.7139.2

Profit before tax, standalone (INR Cr)

395368.0109.3—

Net profit (INR Cr)

31.838.649.182.6103.6

EPS derived, net profit / period-end shares (INR)

2.402.883.626.006.55

Dividend per share (INR)

—0.450.450.450.45

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%) — Operating profit, standalone, Screener

MetricFY2022FY2023FY2024FY2025FY2026

Operating profit, standalone, Screener (INR Cr)

6894128150—

EBITDA, consolidated, Company (INR Cr)

————218.0

EBITDA margin, consolidated (%)

————20.2

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin, aggregator basis (%)

16.618.720.221.122.0

Operating EBIT margin (%)

8.48.710.611.513.1

Net margin (%)

5.75.25.68.89.6

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Cr)

709.7905.0971.51,357.41,428.7

Cash and cash equivalents (INR Cr)

15.722.914.641.633.4

Cash plus short-term investments, aggregator (INR Cr)

27.750.914.641.633.4

Total debt incl. lease liabilities, aggregator (INR Cr)

201.2285.9320.3290.3261.6

Borrowings excl. leases (INR Cr)

190.4268.2304.9280.5226.9

Net debt, aggregator basis (INR Cr)

173.5234.9305.7248.7228.2

Shareholders' equity (INR Cr)

359.4403.1448.4837.7934.7

Other intangible assets (INR Cr)

4.37.57.010.112.3

Total current assets (INR Cr)

127.0170.4180.1535.1366.8

Total current liabilities (INR Cr)

138.2205.8184.6216.1210.8

Net working capital (INR Cr)

-11.2-35.4-4.5319.0156.0

Cash Flow and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (INR Cr)

59.5127.2108.9155.7131.9

Capital expenditure derived (INR Cr)

108.9146.572.693.1104.9

Free cash flow (INR Cr)

-49.4-19.336.362.627.0

Free cash flow margin (%)

-8.9-2.64.16.72.5

Cash interest paid (INR Cr)

11.120.133.031.127.2

Debt issued (INR Cr)

79.182.845.3350.864.2

Debt repaid (INR Cr)

24.627.537.240.380.9

Investing cash flow (INR Cr)

-107.2-158.2-88.1-393.2-90.0

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE on average equity (%)

9.310.111.512.811.7

ROA on period-end assets (%)

4.54.35.16.17.3

Current ratio (x)

0.920.830.982.481.74

Debt to equity incl. leases (x)

0.560.710.710.350.28

Interest coverage EBIT / interest (x)

5.03.73.43.85.8

Asset turnover, revenue / period-end assets (x)

0.780.810.900.690.76

Cash conversion cycle, standalone Screener (days)

47433637—

Income Statement and Margin Analysis (%) (Quarterly)

MetricQ1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Revenue from operations (INR Cr)

255.0274.7272.4279.2287.3

Net profit (INR Cr)

21.330.022.230.331.4

Net margin (%)

8.310.98.210.810.9

Revenue by Region and Revenue by Region (%)

MetricQ3FY26Q4FY26Q1FY27

International patient revenue (INR Cr)

—82.376.5

International share of Gurugram revenue (%)

3430.827.5

International revenue growth YoY (%)

34.913.58.6

Payor Details

PayorShare of revenue (%)

International patients

27

Insured patients

33

Domestic cash patients

23

Government schemes

17

Valuation Snapshot

MetricValueSource

Price (12 Oct 2026)

INR 311.45

Tickertape

Market cap (12 Oct 2026)

INR 4,958 crore

Tickertape / Kotak Neo

52-week high / low

INR 378.80 / INR 203.35

Kotak Neo

1-year return

About +30% (as of 12 Oct 2026)

Kotak Neo

Calendar 2026 YTD

About +40% at 25 Sep 2026, versus Sensex about –12%

Analytics Insight

Share Price

Metric02-Mar-202630-Mar-202620-Apr-202618-Jun-202631-Jul-202622-Aug-202625-Sep-202612-Oct-2026

Closing or quoted price (INR)

229.98205.51229.62259.15299.00326.10378.40311.45

Valuation Snapshot by Multiple

MultipleValueBasis

P/E (TTM)

About 43.6x

TTM PAT of about INR 113.7 crore (FY26 INR 103.6 crore + Q1 FY27 INR 31.4 crore – Q1 FY26 INR 21.3 crore)

P/B

About 5.3x

FY26 equity INR 934.7 crore

EV/EBITDA (TTM)

About 21.5x

EV about INR 4,979 crore (market cap + borrowings INR 226.9 crore – cash and bank INR 206.1 crore); TTM EBITDA about INR 231.5 crore

EV/Sales (TTM)

About 4.5x

TTM revenue about INR 1,113.5 crore

Aggregator P/E

42–45x (Jul–Aug 2026)

Angel One; Torus; ICICI Direct

Broker / Aggregate Details

Broker / aggregateRatingTarget (INR)Date

InCred Equities

Initiation (positive)

437

Sep 2026

Sharekhan

Hold

250

19 Feb 2026

INDmoney aggregate (3 analysts)

—

364 average

Dated snapshot

Sharpely consensus

Buy (100% buy or strong buy)

328

Jul 2026

Capital Markets

ItemDetail

Dividend policy and history

Final dividend of INR 0.45 per share for FY26 (record date 10 Jul 2026); flat in recent years per aggregator; yield about 0.15–0.17%

Buybacks

None authorised

Credit ratings

CareEdge: CARE A; Stable (long-term bank facilities INR 427.90 crore) and CARE A; Stable / CARE A2+ (INR 45 crore long-term/short-term), reaffirmed 12 Aug 2025. No Moody's, S&P or Fitch ratings.

Debt maturity profile

Borrowings of INR 226.9 crore at 31 Mar 2026: INR 36.9 crore current (due within 12 months) and INR 190.0 crore non-current. The detailed maturity ladder is not publicly disclosed in retrieved sources.

Analyst Ratings & Targets

DateRating

Jul 2020

CARE A-; Stable

Sep 2022

CARE A-; Stable

Aug 2023

CARE A-; Stable

Sep 2024

CARE A; Stable (upgrade)

Aug 2025

CARE A; Stable

Analyst Conclusions

Management guidance recap

  • Gurugram occupancy of about 70% by Q2 FY27 and 68–70% for FY27.

  • ARPOB growth of 4–6% a year.

  • Continued absolute EBITDA expansion in FY27.

  • Raipur breakeven within 18–24 months of its July 2026 launch.

  • VIMHANS phase 1 (~450 beds) by FY29.

  • Group capacity of 2,000–2,300 beds by 2029, funded partly by up to INR 700 crore of new equity.

Consensus

A formal consensus for FY27/FY28 revenue and EPS was not publicly available in retrieved sources. Sharekhan's November 2025 model projected FY27 sales of about INR 1,488 crore; that projection assumed earlier Raipur commissioning and should be treated as stale.

Bull case

  1. Utilisation-driven operating leverage. Each point of Gurugram occupancy on about 544 operational beds at an ARPOB of about INR 85,700 adds roughly INR 17 crore of annual revenue at high incremental margin. Q1 FY27 shows the effect: EBITDA +27.9% on revenue +12.7%.

  2. Cheap capacity. 100–125 FAR-bonus beds at no extra land cost, plus MSA hospitals (VIMHANS, Raipur), can grow beds far faster than the capital base, lifting ROE from the current 11–13%.

  3. Valuation gap. At about 44x TTM P/E and about 21x EV/EBITDA, Artemis trades well below the 60–70x P/E of NCR peers Max, Fortis and Medanta. InCred's INR 437 target implies about 40% upside.

Bear case

  1. Concentration plus competition. About 97% of revenue comes from one hospital, in a micro-market where Medanta and Fortis are adding capacity. Any share loss or doctor attrition hits the whole P&L.

  2. Dilution and gestation. Up to INR 700 crore of equity (about 14% of market cap), Raipur losses for 18–24 months and falling treasury income could stall EPS growth in FY27–FY28 even as EBITDA grows.

  3. International-patient fragility. The flagship's highest-margin channel slowed from +34.9% to +8.6% YoY within two quarters on geopolitics. The 44.5% promoter pledge adds overhang risk.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhat to watch
Q2 FY27 resultsEarly Nov 2026 (window closed from 1 Oct)Whether occupancy reached 70%; first-quarter Raipur losses; international revenue trend
INR 700 crore QIP / preferential pricingH2 FY27Issue price versus market; investor quality; use of proceeds
Commissioning of 100 incremental Gurugram bedsOnce occupancy is at least 70%Timing and ramp
Raipur ramp-upFY27–FY28Occupancy, ARPOB, EBITDA loss trajectory
VIMHANS constructionStarted Apr–May 2026Milestones toward FY29
New MSA or acquisition announcementsFY27Deal terms and capital intensity
CGST show-cause outcomeFY27Final liability
CareEdge annual surveillanceAbout Aug 2027Rating direction post-raise
Promoter pledge changesQuarterly shareholdingRelease or increase

Analyst verdict

Artemis Medicare enters FY27 with the strongest operating momentum in its listed history. Consolidated revenue compounded at about 18% from FY22 to FY26, reaching INR 1,081 crore. Net profit more than tripled from INR 31.8 crore to INR 103.6 crore. Q1 FY27 delivered a record operating margin of about 19.6% (excluding other income) on rising occupancy (65.7%) and pricing (ARPOB INR 85,690). The balance sheet that once constrained growth has been repaired. The IFC CCD conversion and steady cash generation cut debt/equity to about 0.28x, and the CareEdge upgrade to A captured the improvement.

The open question is whether a single, high-quality hospital can become a scalable network without sacrificing its returns profile. The asset-light MSA approach (Raipur, VIMHANS) and the FAR-led brownfield are sensible answers in principle. They let Artemis add beds with far less capital per bed than a greenfield build. However, the model also introduces new risks: partner dependence, gestation losses at Raipur and dilution from the INR 700 crore raise. Disclosure on these arrangements has so far been thin. Meanwhile, the flagship's most profitable channel, international patients, has decelerated sharply on West Asia disruption. Competition in Gurugram intensifies as Medanta and others add beds.

At about 44x trailing earnings and about 21x EV/EBITDA, the market is pricing in a successful transition, though at a meaningful discount to large NCR peers. We view the risk-reward as constructive but execution-dependent. Three things would validate the bull case over the next 12 months: occupancy crossing 70% (unlocking the deferred 100 beds), QIP pricing at or above about INR 300 with quality long-only participation, and Raipur losses tracking the 18–24-month breakeven guidance. Failure on any two would likely push the stock back toward the Sharekhan-style valuation anchor of about 26x forward earnings. Investors should also track the 44.5% promoter pledge closely.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundCompensation (FY26)

Onkar S. Kanwar

Chairman (promoter)

Founder-promoter since 2004

Chairman of Apollo Tyres Ltd; heads the promoter group holding through Constructive Finance Pvt Ltd

Not publicly disclosed in retrieved sources

Dr. Devlina Chakravarty

Managing Director (MD & CEO, Artemis Hospitals Group)

MD/Executive Director since 2 Feb 2015 (CEO from Jan 2014 per Simply Wall St); re-appointment approved by the Board on 14 Nov 2024 and by postal ballot on 26 Dec 2024

Physician (MD, DNB, DMRD – Radiology); about 2.5% direct shareholding per a dated Simply Wall St snapshot

Not publicly disclosed in retrieved sources

Poonam Makkar

Company Secretary & Compliance Officer

———

Rudra Narayan Acharjee

Head – Investor Relations, M&A and Organisation Growth Strategy (Senior Management)

From 18 Sep 2025

——

Dr. Sandeep G. Attawar

Clinical lead, Heart & Lung Transplant Centre

2,026

Decades of experience setting up thoracic transplant programmes in India

Not applicable

“—” = not publicly disclosed.

Governance Overview

AttributeDetailSource

Board size

10 directors (FY26), down from 11 at 31 Mar 2025

BRSR FY26; FY25 Directors' Report

Composition at 31 Mar 2025

1 Executive, 4 Non-Executive, 6 Independent (including 2 women)

FY25 Directors' Report

Gender

3 of 10 directors are women (30%)

BRSR FY26

Chair/CEO separation

Yes: Non-Executive promoter Chairman (Onkar Kanwar) and a separate MD (Dr. Chakravarty)

Filings

Recent change

Independent Director Sanjib Sen (DIN 07088442) ceased on completing his tenure, 2 Aug 2026

Exchange disclosure, 3 Aug 2026

Committees

Statutory committees under SEBI LODR (Audit, Nomination & Remuneration, Stakeholders' Relationship, CSR, Risk Management); a Board committee reviews BRSR/NGRBC principles

—

IFC rights

Policy Rights Agreement with IFC (2024) gives IFC certain special rights, approved at the 3 May 2024 EGM

Digital Health News

Internal auditor

Prateek Rastogi, CA, appointed from 12 Nov 2025

Board outcome, 11 Nov 2025

Secretarial auditor

Ankit Tiwari & Co. (per 22nd AGM proceedings)

NSE AGM disclosure

Shareholding Trend

Holder categoryDec 2025Mar 2026Jun 2026

Promoter and promoter group (%)

58.3858.3958.39

Institutions (%)

21.5321.2420.84

Non-institutions (%)

20.0720.3620.76

Major Shareholders

HolderStake (%)TypeSource

Constructive Finance Private Limited

58.38

Promoter holding company

MarketsMojo, Jun 2026

International Finance Corporation

11.98

Multilateral / FPI

MarketsMojo, Jun 2026

Body corporate where Central/State Government is promoter (3,000,000 shares; name not shown)

1.90

Institutional

Shareholding pattern, Mar 2026

AMSL Unclaimed Suspense Account

1.48

Legacy unclaimed shares

Shareholding pattern, Mar 2026

Mutual funds (5 schemes)

1.30 (Jun 2026); 0.92 (Oct 2026 per Kotak)

DII

MarketsMojo; Kotak Neo

Other FIIs (21 FIIs in aggregate including IFC)

12.29 total FII

FPI

MarketsMojo

Onkar Kanwar (individual)

0.01

Promoter individual

Shareholding pattern

Individual investors

12.79

Retail

MarketsMojo

Competitive Landscape

Key Competitors

CompetitorListed entityOverlap with ArtemisRelative positioning

Medanta – The Medicity, Gurugram

Global Health Ltd (MEDANTA)

Direct; same city, quaternary, international patients

Much larger scale; capacity grew 20% in FY26

Fortis Memorial Research Institute, Gurugram

Fortis Healthcare (FORTIS)

Direct; Gurugram quaternary and transplants

National chain scale

Max Super Speciality (Saket and Gurugram)

Max Healthcare (MAXHEALTH)

Direct in NCR; oncology and cardiac

Highest NCR scale and margins

Apollo Indraprastha, New Delhi

Apollo Hospitals (APOLLOHOSP)

NCR tertiary; international patients

Largest listed chain

Manipal Hospitals (Dwarka, Gurugram)

Manipal Health (listing status per aggregator: MANIPALHOS)

NCR multi-specialty

Pan-India scale

Narayana Health, Gurugram

Narayana Hrudayalaya (NH)

Cardiac, Gurugram

Cost-leadership model

Paras Health, Gurugram

Unlisted

Gurugram tertiary

Regional

CK Birla, Marengo Asia, W Pratiksha (Gurugram)

Unlisted

Gurugram multi-specialty

Regional

Sir Ganga Ram, BLK-Max, Indian Spinal Injuries Centre

Trust / partly listed

Delhi tertiary

Referral competition

Yatharth Hospital, Park Hospital (NCR)

Listed small caps

NCR mid-market

Lower ARPOB

Raipur: Ramkrishna CARE, NH MMI Raipur, AIIMS Raipur, Shri Balaji

Mixed

Raipur tertiary

Incumbents Artemis must displace

Medical-tourism peers: Medanta, Fortis, Apollo, Max

Listed

International patient share

Artemis' 27–34% mix is among the highest in its peer set

Peer Comparison FY2026

CompanyMarket cap (INR Cr)P/E (x)Annual PAT (INR Cr)

Apollo Hospitals

126,30060.51,942

Max Healthcare

96,76366.41,442

Fortis Healthcare

68,90165.81,042

Global Health (Medanta)

38,14968.6556

Narayana Hrudayalaya

38,43947.1806

Artemis Medicare

5,06344.6104

Company Snapshot

$124.8M

Revenue

2004

Founded

Gurugram, India

Headquarters

SWOT Analysis

Strengths

  • Premium pricing. Gurugram ARPOB was INR 85,690 in Q1 FY27; FY26 ARPOB was INR 82,435, up 7.8% from INR 76,447 in FY25 (Q1 FY27 and FY26 releases).
  • International patient franchise. It contributed 27.5–34% of flagship revenue through FY26–Q1 FY27, and 32% for 9M FY26.
  • Operating leverage now visible. Q1 FY27 EBITDA grew 27.9% and PAT 48.3% on 12.7% revenue growth.
  • Deleveraged balance sheet. Debt/equity (including leases) fell to 0.28x by FY26 from 0.71x in FY24. Borrowings were INR 226.9 crore against INR 206 crore of cash and bank balances.
  • Credit upgrade trajectory. The rating moved from CARE A- (2020–2023) to CARE A; Stable (Sep 2024), and was reaffirmed in Aug 2025.
  • Marquee investor validation. IFC invested INR 330 crore and now holds about 12%.

Weaknesses

  • Single-asset concentration. Gurugram produced 96.9% of consolidated revenue in Q1 FY27.
  • Sub-par utilisation. Occupancy was 61–66% through FY26–Q1 FY27, with only 544 of 700 Gurugram beds operational.
  • Modest returns. The three-year average ROE is about 11.7% (Screener), and ROE was 11.7% in FY26 (computed).
  • Volatile FCF. FCF fell to INR 27 crore in FY26 from INR 62.6 crore in FY25, and was negative in FY22–FY23.
  • Promoter pledge. 44.5% of promoter shares are encumbered.
  • Thin disclosure. There is no segment, OP/IP or country split, and limited KMP compensation detail in accessible releases. Raipur bed counts conflict between sources (200 vs. 300+).

Opportunities

  • FAR-led brownfield. The 15% FAR bonus adds 100–125 beds at no extra land cost, and purchased FAR adds about 200 beds, taking Gurugram to 950–1,000 beds.
  • VIMHANS South Delhi MSA. 450 to 650+ beds in a premium catchment, by FY29.
  • Raipur and the Central India gateway. 300+ beds and 11 CoEs; management describes Raipur as an emerging tertiary/quaternary hub.
  • Occupancy to 70%. This would add about 5 points of utilisation on the existing base (guided).
  • INR 700 crore equity raise. It funds inorganic growth with the IR/M&A head already in place.
  • Transplant and quaternary programmes. The 2026 Heart & Lung Transplant Centre supports further ARPOB growth (guided at 4–6% a year).

Threats

  • Geopolitical disruption to medical travel. International growth slowed to +8.6% in Q1 FY27 from +34.9% in Q3 FY26.
  • NCR competitive intensity. Medanta added 20% capacity in FY26; Fortis and Max are in the same catchment.
  • Gestation drag. Raipur breakeven is guided at 18–24 months; Sharekhan flagged near-term bottom-line stress from heavy capex.
  • Equity dilution. Up to INR 700 crore is roughly 14% of the current INR 4,958 crore market cap.
  • Tax and regulatory exposure. The CGST show-cause notice is for INR 11.11 crore plus interest and penalty (Sep 2026); government-scheme pricing caps apply to 17% of the mix.
  • Falling other income. Treasury income from IFC funds is declining as funds are spent (Q1 FY27), removing a PAT tailwind.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
12 May 2025Board approves a director/KMP appointment (detail truncated in source)Governance
Jul–Aug 2025Q1 FY26 results: revenue about INR 250–255 crore (+15%), PAT INR 21.28 crore (+27.7%)Steady growth
12 Aug 2025CareEdge reaffirms CARE A; Stable / A2+; long-term facilities enhanced to INR 427.90 croreCredit stability
Q1 FY26Monitoring agency report on IFC preferential-issue proceeds used for expansionUse-of-proceeds compliance
18 Sep 2025Rudra Narayan Acharjee named Head of IR, M&A and Growth StrategySignals an M&A agenda
17 Oct 20253.06 lakh ESOP shares allottedMinor dilution
11 Nov 2025Q2 FY26 results: revenue INR 274.7 crore; PAT INR 30.0 crore (+34.6%); H1 PAT INR 51.38 crore. Raipur then targeted for Mar 2026. New internal auditor appointed.Margin step-up
Nov 2025IFC CCDs converted into 1.89 crore sharesDeleveraging; IFC becomes an ~12% holder
18 Nov 2025Sharekhan initiation: 1,700+ beds by FY29Sell-side coverage
2 Feb 2026Q3 FY26: revenue +17.2% to INR 272 crore; EBITDA +12.5%; PAT +7.9% to INR 22.2 crore; ARPOB INR 84,100Margin dip from Tower-3 costs
3 Feb 2026Q3 call: 2,300 beds by 2029; INR 700 crore raise; Raipur slips to Apr–May 2026Strategy reset to growth
19 Feb 2026Sharekhan retains Hold, price target INR 250Valuation caution
20 Feb 2026VIMHANS Artemis Hospital MSA (650+ beds, South Delhi)Largest capacity addition
2 Mar 2026Stock closes at INR 229.98 (–4.1%) on the dilution overhangMarket reaction
30 Mar – Apr 2026Stock hits its 52-week low (INR 203.35 NSE / INR 202.85 BSE)Sentiment trough
29 Apr 2026Disclosure that AMSL is not a "large corporate"; borrowing of INR 225.70 croreLeverage transparency
8 May 2026Q4/FY26: revenue +16.4% (Q4) and +15.4% (FY) to INR 1,081 crore; Q4 PAT +32.1%; dividend of INR 0.45 recommendedRecord year
11 May 2026Q4 call: 70% occupancy target; 100 incremental beds gated on occupancy; Raipur breakeven in 18–24 monthsGuidance
3 Jun 2026Artemis Shanti Hospital, Raipur announced (300+ beds, 11 CoEs)Central India entry
c. Jun 2026Heart & Lung Transplant Centre inauguratedQuaternary capability
18 Jun 2026Board approves fund-raise of up to INR 700 crore (postal ballot route)Capital
7 Jul 2026BRSR FY26 filed (IGBC Platinum; 30% women on the board)ESG disclosure
9 Jul 2026Raipur hospital commences operationsCapacity milestone
20 Jul 2026Shareholders approve the fund-raiseRemoves approval risk
31 Jul 202622nd AGM: dividend approved; auditor re-appointed to 2031Governance continuity
2–3 Aug 2026Independent Director Sanjib Sen's tenure endsBoard refresh
3–4 Aug 2026Q1 FY27: revenue +12.7% to INR 287.3 crore; EBITDA +27.9% to INR 61.8 crore; PAT +48.3% to INR 31.4 crore; occupancy 65.7%; ARPOB INR 85,690Operating leverage evident
3 Sep 2026Investor conference in DelhiIR engagement
10 Sep 2026Stock at a prior high of INR 361.50Momentum
23 Sep 2026Q1 FY27 call transcript summary: 70% occupancy by Q2 FY27Guidance reiterated
25 Sep 2026InCred Equities initiates with a target of INR 437; stock rises up to 14% to an all-time high of INR 378.40 on about 12.75 million shares tradedRe-rating
28 Sep 2026Trading window closed from 1 Oct until Q2 FY27 resultsQ2 results imminent
29 Sep 2026CGST Gurugram show-cause notice (FY23): INR 11.11 crore plus interest and penaltyTax contingency
6 Oct 2026Reg. 74(5) dematerialisation certificate for Q2 FY27 (Alankit Assignments)Routine
Oct 2026Exchange filing on the appointment of a "Dr." (details truncated in source)Governance / clinical leadership
12 Oct 2026Price INR 311.45; market cap about INR 4,958 croreAbout 18% below the all-time high

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue from operations rose from INR 5,548 Mn in FY2022 to INR 10,812 Mn in FY2026.
Artemis Medicare Services Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations5,5487,3748,7869,36910,812
Gross profit, aggregator basis9191,3811,7761,9772,377

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Indian Pharma Post – Q1 FY27 results (indianpharmapost.com)
  2. Indian Pharma Post – Q4 FY26 results (indianpharmapost.com)
  3. Sahi – Q1 FY27 filing summary (sahi.com)
  4. Multibagg – Q1 FY27 update (multibagg.ai)
  5. MarketsMojo – Q1 FY27 analysis (marketsmojo.com)
  6. ScanX – Q1 FY27 / investor conference (scanx.trade)
  7. Arthneeti – Q1 FY27 and Q4 FY26 call notes · arthneeti.com
  8. Q3 FY26 press release (BSE via Business Standard) (bsmedia.business-standard.com)
  9. Q3 FY26 call transcript (bsmedia.business-standard.com)
  10. AlphaStreet – Q3 FY26, Q4 FY26 transcripts and Q1 FY26 summary · alphastreet.com · alphastreet.com · alphastreet.com
  11. Equitybulls – Q4 FY26 release (equitybulls.com)
  12. ScanX – FY26 results and dividend (scanx.trade)
  13. NSE – VIMHANS MSA intimation (nsearchives.nseindia.com)
  14. NSE – 22nd AGM proceedings and auditor re-appointment · nsearchives.nseindia.com
  15. NSE – FY26 integrated filing (iXBRL) (nsearchives.nseindia.com)
  16. NSE – Board outcome, 11 Nov 2025 (nsearchives.nseindia.com)
  17. IIFL – FY25 Directors' Report (indiainfoline.com)
  18. ScanX – BRSR FY26 (scanx.trade)
  19. CareEdge rating releases (2020, 2022, 2023, 2024, 2025) · careratings.com · careratings.com
  20. BSE – IFC press release (5 Apr 2024) (bseindia.com)
  21. BioSpectrum – IFC fund-raise completion (biospectrumindia.com)
  22. ScanX – IFC CCD conversion (scanx.trade)
  23. Angel One – QIP plan; company profile · angelone.in
  24. Sharekhan research notes (Nov 2025; Feb 2026) · sharekhan.com
  25. Medical Dialogues / Digital Health News – Raipur · digitalhealthnews.com
  26. BioVoice / India MedToday – Heart & Lung Transplant Centre · indiamedtoday.com
  27. Analytics Insight – record high and InCred initiation (analyticsinsight.net)
  28. StockAnalysis – income statement, balance sheet, cash flow · stockanalysis.com · stockanalysis.com
  29. Screener (screener.in)
  30. Fyers – results and peer comparison (fyers.in)
  31. Arihant Capital / CMOTS – balance sheet and price history (arihantcapital.com)
  32. MarketsMojo – shareholding (marketsmojo.motilaloswal.com)
  33. IIFL – shareholding (indiainfoline.com)
  34. Tickertape / Kotak Neo – price, market cap, announcements · kotakneo.com
  35. Simply Wall St – management (simplywall.st)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.